Catecholamines and the sleep-wake cycle. I. EEG and behavioral arousal - PubMed (original) (raw)
Review
Catecholamines and the sleep-wake cycle. I. EEG and behavioral arousal
J M Monti. Life Sci. 1982.
Abstract
The exact role of catecholamines (CA) on the sleep-wake cycle is still controversial. Critical analysis of lesion studies tends to suggest a neuromodulatory role for both dopamine (DA) and norepinephrine (NE) on EEG and behavioral arousal. Support for this view is provided by pharmacological studies in which catecholaminergic systems are activated or inhibited. Taken together they show that disturbances in the dynamic balance between neurochemical systems may alter the conditions for wake-triggering mechanisms to express at optimal levels. Large electrolytic or neurotoxic lesions which affect noradrenergic and dopaminergic structures are associated with marked and prolonged EEG changes and decreased behavioral arousal, respectively. In contrast, specific and circumscribed damage restricted to these systems is followed by a transient decrease in waking activity. Thus, results observed after large central lesions are most probably related to destruction of non-catecholaminergic neurons. Inhibition of brain CA synthesis causes behavioral sedation and a decrease in waking activity. Selective pharmacological stimulation of presynaptic alpha-adrenergic (alpha 2) receptors tends to decrease waking, while opposite effects result from alpha 2-receptor blockade. Drugs with agonistic activity at postsynaptic alpha-adrenergic (alpha 1) sites increase EEG desynchronization, but specific blockade of alpha 1-receptor does not result in marked decreases of waking EEG. In contrast, treatments which simultaneously block NE and DA receptors significantly affect waking. Beta-adrenergic receptor blockers show no conclusive effects on waking or sleep. Selective DA-receptor agonists induce biphasic effects, with low doses decreasing and large doses increasing cortical desynchronization and motility. Opposite effects are observed in laboratory animals after injection of specific DA-receptor blockers.
Similar articles
- The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
Monti JM, Jantos H. Monti JM, et al. Prog Brain Res. 2008;172:625-46. doi: 10.1016/S0079-6123(08)00929-1. Prog Brain Res. 2008. PMID: 18772053 Review. - The involvement of dopamine in the modulation of sleep and waking.
Monti JM, Monti D. Monti JM, et al. Sleep Med Rev. 2007 Apr;11(2):113-33. doi: 10.1016/j.smrv.2006.08.003. Epub 2007 Feb 1. Sleep Med Rev. 2007. PMID: 17275369 Review. - Neurotoxic lesion of the mesencephalic reticular formation and/or the posterior hypothalamus does not alter waking in the cat.
Denoyer M, Sallanon M, Buda C, Kitahama K, Jouvet M. Denoyer M, et al. Brain Res. 1991 Jan 25;539(2):287-303. doi: 10.1016/0006-8993(91)91633-c. Brain Res. 1991. PMID: 1675907 - [Selective stimulations and lesions of the rat brain nuclei as the models for research of the human sleep pathology mechanisms].
Šaponjić J. Šaponjić J. Glas Srp Akad Nauka Med. 2011;(51):85-97. Glas Srp Akad Nauka Med. 2011. PMID: 22165729 Review. Serbian. - Adrenergic signaling plays a critical role in the maintenance of waking and in the regulation of REM sleep.
Ouyang M, Hellman K, Abel T, Thomas SA. Ouyang M, et al. J Neurophysiol. 2004 Oct;92(4):2071-82. doi: 10.1152/jn.00226.2004. Epub 2004 Jun 9. J Neurophysiol. 2004. PMID: 15190089
Cited by
- Sleep during and following critical illness: A narrative review.
Showler L, Ali Abdelhamid Y, Goldin J, Deane AM. Showler L, et al. World J Crit Care Med. 2023 Jun 9;12(3):92-115. doi: 10.5492/wjccm.v12.i3.92. eCollection 2023 Jun 9. World J Crit Care Med. 2023. PMID: 37397589 Free PMC article. Review. - Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis.
Merino D, Gérard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Viard D, Rocher F, Destere A, Benoit M, Drici MD. Merino D, et al. J Clin Med. 2022 Jul 4;11(13):3890. doi: 10.3390/jcm11133890. J Clin Med. 2022. PMID: 35807172 Free PMC article. - Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.
Bliwise DL, Trotti LM, Wilson AG, Greer SA, Wood-Siverio C, Juncos JJ, Factor SA, Freeman A, Rye DB. Bliwise DL, et al. Mov Disord. 2012 Aug;27(9):1118-24. doi: 10.1002/mds.25082. Epub 2012 Jul 2. Mov Disord. 2012. PMID: 22753297 Free PMC article. - Psychoses and creativity: is the missing link a biological mechanism related to phospholipids turnover?
Folley BS, Doop ML, Park S. Folley BS, et al. Prostaglandins Leukot Essent Fatty Acids. 2003 Dec;69(6):467-76. doi: 10.1016/j.plefa.2003.08.019. Prostaglandins Leukot Essent Fatty Acids. 2003. PMID: 14623501 Free PMC article. - Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.
Nishino S, Mignot E. Nishino S, et al. Clin Pharmacokinet. 1999 Oct;37(4):305-30. doi: 10.2165/00003088-199937040-00003. Clin Pharmacokinet. 1999. PMID: 10554047 Review.